The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Highlights in lung cancer at ESMO 2023: PAPILLON and MARIPOSA
Guillaume Eberst, MD, University Hospital of Besancon, Besancon, France, shares his highlights in lung cancer at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. Dr Eberst states the new standard of care achieved in treatments for patients with lung cancer from trials such as PAPILLON (NCT04538664) which monitored the effect of amivantamab alongside carboplatin-pemetrexed chemotherapy and MARIPOSA (NCT04487080), which assessed amivantamab and lazertinib versus osimerinib in EGFR-mutant non-small cell lung cancers are his personal favourites at this year’s ESMO, with the potential to improve patient outcomes significantly.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
